In most patients with haematological malignancies treated with chemotherapy, growing resistance to cytostatics is observed. Multidrug resistance (MDR) is caused by enhanced cellular drug efflux following an increased activity of a membrane cell bound P-glycoprotein (Pgp), which is encoded by the mdr1 gene. Primary MDR in multiple myeloma (MM) is a rare, poorly understood phenomenon. A number of recent reports have shown that thalidomide (THAL) is an efficient drug in patients with refractory to chemotherapy MM.
A 68-year-old male patient with advanced MM was referred to the Haematology Department of the Medical University in Lublin in March 1996. The stage III B (acc. to the Durie and Salmon criteria) IgGk with À13q deletion (FISH) was established. A skeletal survey demonstrated advanced osteolytic lesions. Bone marrow aspiration showed a high percentage of atypical plasma cells (50%). The patient presented with a total protein serum level above 14 g/dl, with g-globulin fraction 56% and serum IgG 10.0 g/dl. Beta-2-microglobulin serum level was very high (8.5 mg/l), and patient displayed the first signs of renal failure. At the time of diagnosis, Pgp expression was found in 92% of bone marrow plasma cells using RT-PCR analysis. There was also a high expression of mdr1 gene in bone marrow mononuclear cells. In spite of several lines of chemotherapy given during 24 months, the patient did not achieve haematological remission (Figure 1 ). We decided to cease further chemotherapy regimens and start therapeutic plasmaphereses using TPP programme of cell separator Haemonetics MCS-3p. At the same time the patient received two courses of high-dose methylprednisolone and because of apparent anaemia, erythropoietin therapy was started in a dose of 10.000 IU three times a week. The result of this therapeutical combination was transitory improvement of the patient's performance status.
After 6 months the rapid progression of the disease was observed. With regard to exhaustion of chemotherapy possibilities, in March 1999 the patient was qualified to THAL treatment, after signing an informed consent and achieving a local Ethical Committee approval. THAL (Gruenenthal, Germany) was started from a dose of 200 mg daily, administered orally in two separate doses. The dose was then increased by 100 mg every 7 days of the therapy, reaching 400 mg daily in the third week of the therapy. In the sixth week of THAL treatment, an improvement of performance status was associated with a decrease in serum protein level from 14 to 9 g/dl. During next 4 months gradual normalisation of the haemoglobin level was observed, and succeeding blood cell count showed normal platelet count (above 170 g/l) and moderate leukopenia (3.073.5 g/l), which was also seen in this patient before THAL treatment. Clinical parameters before and during THAL therapy are shown in Figure 1 .
After 6 months of THAL therapy, bone marrow biopsy showed a reduction of malignant plasma cells phenotype (CD38/CD138) by more than 50% compared to the values before treatment. After 36 months of THAL therapy, 3% of plasma cells were found in a bone marrow aspirate, and 3.9% of these cells with phenotype CD38 þ þ þ , CD138 þ , CD19À and CD45À.
Analysis of mdr1 gene expression in bone marrow mononuclear cells performed by RT-PCR method did not show the presence of mdr1 mRNA neither after 24, nor after 48 months from the start of THAL therapy (Figure 2 ).
After 36 months of THAL treatment, the dose was reduced from 400 to 200 mg daily due to progressive polyneuropathy. After 42 months, THAL was withdrawn. Apart from drowsiness, temporary constipation and polyneuropathy (stage 2 acc. WHO), we did not observe any other adverse events. At present, 60 months from the start of THAL therapy and 18 months from the THAL treatment cessation the patient is still in a complete haematological remission.
MM still remains an incurable disease. It is most often diagnosed in the elderly, almost always with coexisting diseases overburdening their general condition and restricting therapeutical options to melphalan therapy or cytotoxic drug combination regiments. Even in younger patients, in whom due to different reasons autologous peripheral blood stem cell transplantation cannot be performed, the disease soon causes systemic complications, most often recurrent infections, massive bone destruction, renal failure and chemotherapy-induced bone marrow failure. For many patients, apart from palliative treatment and blood compounds substitution, there is no effective therapy controlling a continuous disease progression. A significant problem is a primary MDR, which can be confirmed by estimating mdr1 gene and Pgp expression in plasma cells. The mdr1 gene expression is suggested as one of the major mechanisms of MDR in human cancers, including haematological malignancies. 1 Primary resistant to chemotherapy MM patients do not respond to first-line treatment and some of these patients have rapidly evolving MM while on induction therapy. For patients primary refractory to melphalan and prednisone VAD or highdose steroids are treatment of choice. The problem is more complicated for patients who fail to respond to VAD or highdose corticosteroids or who are primary resistant to VAD as a first-line therapy. In order to reverse the expression of the mdr1 gene different attempts were undertaken, such as highdose verapamil or its analog PSC 833 or cyclosporine addition, but these attempts were effective only in about 20% of VAD-resistant MM for a start period. Compared to VAD regimen alone, addition of verapamil or cyclosporine did not significantly improve patients median survival.
2,3 It is known that etoposide-based regimens, such as EDAP (etoposide, dexamethasone, cisplatin, cytarabine) have shown some effect in VAD-resistant patients, but patients with elevated beta-2-microglobulin are less likely to benefit from this regimen.
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Over the last 10-15 years several new drugs have been introduced to resistant/relapsed patients with MM. Among the most efficient drugs, THAL was the most promising one. 5, 6 Hideshima et al 7 for the first time showed that THAL and its analogues overcome MDR of human MM cell lines, which were resistant to doxorubicin, mitoxantrone and melphalan. The optimum dose and duration of the treatment with THAL for relapsed or refractory MM are not known. What is more, it has not been clarified yet, whether the activity of THAL is related to the administered dose. We present a case of a patient with a refractory MM effectively treated with a medium dose of 400 mg/day for over 3 years (cumulative dose at 3 months 34.5 g), which resulted in a complete haematologic remission and reversing MDR with a molecular confirmation of the lack of mdr1 gene expression.
THAL and its analogues have opened a new era in the treatment of refractory MM; thus the exact mechanisms of their action are still under investigation. THAL and its analogues induce cytotoxicity and apoptosis in MM cells and in addition the drug does not show even the slightest crossresistance with other antineoplastic agents. It seems that except for immunomodulative and antiangiogenetic action of THAL, overcoming MDR might significantly influence improvement of MM patients survival.
Figure 1
Serum total and monoclonal protein level, percentage of bone marrow plasma cells and beta-2-microglobulin level before, during and after thalidomide treatment. Before introduction of thalidomide therapy the patient received numerous chemotherapy regimens: VID -vincristine, idarubicine and dexamethasone (1996), VMBCP-vincristinre, melphalan, BCNU, cyclophosphamide and prednisone (1996), VAD -vincristinre, adriamycine and dexamethason (1997), cyclophosphamide and etoposide (1997), melphalan (1997), high-dose steroids (1998), cyclophosphamide and cyclosporine (1998), vinorelbine (1998), and high-dose steroids (1999). Moreover, the patient required plasmapheresis (1998). In march 1999 THAL was started from a dose of 200 mg daily reaching 400 mg daily in the 3rd week of the therapy. After 42 months THAL was withdrawn due to polyneuropathy (grade 2 acc. WHO). At the moment the patient has not been given any treatment for 18 months from THAL withdrawal and he is still in complete haematological remission with a very good performance status.
Figure 2
Results of RT-PCR analysis from the patient with myeloma before, after 24 and 48 months of THAL treatment. From each sample 2 mg of total RNA was analysed and the expression of mdr1 and G3APDH genes was measured (expected fragment size: 229 and 358 bp,respectively). Lane 1 -bone marrow sample before THAL treatment, lane 2 -bone marrow sample after 24 months of THAL treatment, lane 3 -bone marrow sample after 48 months of THAL treatment. The mdr1 gene expression was detected before treatment (lane 1) and was not detected after 24 months (lane 2) and after 48 months (lane 3). The control represents the expression of G3APDH (lanes 1-3) . G3APDH was used as an internal standard for RNA isolation and reverse-transcription efficiency. However, its clinical significance and function in leukemogenesis is still unclear. In the present study, we detected EDAG mRNA expression in a panel of leukemia cell lines and the bone marrow mononuclear cells (BMMC) of 75 acute myeloid leukemia (AML) patients to explore the clinical significance of EDAG. Then we investigated the effect of EDAG gene knockdown by RNA interference (RNAi) on leukemia cell line K562 to study the molecular mechanism.
High expression of EDAG and its significance in AML
The expression of EDAG mRNA in the leukemia cell lines and other samples were detected by semiquantitative RT-PCR. The PCR conditions and the numbers of cycles were chosen according to preliminary experiments in which the amount of product was directly proportional to the quantity of starting cDNA. In summary, total cellular RNA was extracted with the use of Trizol Reagent (Invitrogen). mRNA from 1 mg of total cellular RNA was reverse transcribed using an M-MLV reverse transcriptase commercial kit (Invitrogen). cDNA (2 ml) was amplified by PCR at 941C for 30 s, X1C for 30 s, 721C for 60 s with 30 cycles. X refers to the annealing temperature (Table 1) . The results showed that a high level of EDAG transcripts was detected in K562, KG-1a, Jurkat, Namalva and cord blood CD34 þ cells. A low level of expression was found in Raji, EBV transformed lymphoblastoid cell line LCL-H, hepatoma cell line SMMC-7721, U937 and normal adult bone marrow. However, no expression was detected in HL-60, NB4, J6-1 (derived from a myelomonocytic leukemia patient in 1976) 3 cells. The different expression patterns of EDAG in various leukemia cell lines suggest that EDAG mRNA levels may vary in different leukemia patients. In this study, we also analyzed EDAG mRNA expression in the bone marrow of 75 AML patients (65 with de novo AML and 10 with complete remission (CR) at the time of sample collection) and 15 normal donors. The patients' clinical characteristics are summarized in Table 2 . The diagnosis was based on FAB by standard morphological, cytochemical and immunophenotypic criteria. For statistical analysis, Wilcoxon rank-sum test (Mann-Whitney U test) was used for two-group means comparison; Kruskal-Wallis test (ANOVA) was used for more than two means comparison. EDAG mRNA was expressed in BMMC of all cases detected. In de novo AML patients, its relative expression averaged 0.6470.28, which was significantly higher than that in the normal donors (0.3570.11). We did not detect a marked difference between the CR AML patients (0.3870.16) and the normal donors. We further investigated whether EDAG expression related to the leukemia patients' clinical characteristics. No significant differences were found when the patients were divided into different groups regarding age, sex, initial WBC count, FAB subtype and CD34 expression (Table 2) . Of the 65 de novo AML patients, 53 received therapy in our hospital. A total of 35 patients achieved CR within two courses of standard induction therapies. Interestingly, we found
